2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. TrxR

TrxR

Thioredoxin Reductase

TrxR (Thioredoxin Reductase) is a selenium-containing pyridine nucleotide-disulphide oxidoreductase. There are three isoforms of mammalian TrxRs: TrxR1 (TXRND1), TrxR2 (TXNRD2) and TrxR3 (TGR). TrxRs catalyze the NADPH-dependent reduction of the redox protein thioredoxin (Trx). TrxR is important in regulating the intracellular redox environment, cell growth and transformation, as well as the recycling of ascorbate from its oxidized form. Trx/TrxR system is associated with the cancers, metabolic syndrome, insulin resistance, and type 2 diabetes, as well as in hypertension and atherosclerosis[1][2].

TrxR Isoform Specific Products:

TrxR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146307
    TrxR-IN-3
    TrxR-IN-3 (Compound 2c) is a potent inhibitor of TrxR. TrxR-IN-3 exhibits potent antiproliferative activities against five human cancer cell lines, especially against breast tumor cells. TrxR-IN-3 increases ROS levels and resulted in marked apoptosis by regulating apoptosis-related proteins expressed in the breast cancer cells. TrxR-IN-3 also triggers the formation of autophagosomes and autolysosomes by promoting the expression of LC3-II and Beclin-1 and diminishing the expression of LC3-I and p62 proteins.
    TrxR-IN-3
  • HY-149390
    TrxR1-IN-1
    		Inhibitor
    TrxR1-IN-1 (Compound 5j) is a TrxR1 inhibitor (IC50: 8.8 μM). TrxR1-IN-1 has anticancer activity, with IC50s of MCF-7 (1.5 μM), HeLa (1.7 μM), BGC-823 (2.4 μM), SW-480 (2.8 μM), A549 (2.1 μM). TrxR1-IN-1 has antioxidant activity, and scavenges DPPH radical.
    TrxR1-IN-1
  • HY-P2759A
    Thioredoxin Reductase, E.coli
    Thioredoxin Reductase, E. coli (EC 1.8.1.9) is an E. coli-derived thioredoxin reductase (TrxR) that, compared to mammalian TrxR, lacks the redox active site-the C-terminal -Cys-SeCys-.
    Thioredoxin Reductase, E.coli
  • HY-175806
    CS47
    		Inhibitor
    CS47 is a Thioredoxin Reductase 1 (TRXR1) inhibitor and ferroptosis inducer. CS47 binds non-covalently to sites between the FAD and NADPH pockets of TRXR1. CS47 drives glutathione depletion, lipid reactive oxygen species accumulation, HMOX1-dependent iron overload, and selective cytotoxicity in lung cancer cells. CS47 can be used for the research of lung cancer.
    CS47
  • HY-157158
    TrxR-IN-6
    		Inhibitor
    TrxR-IN-6 is a thioredoxin reductase (TrxR) inhibitor. TrxR-IN-6 induces reactive oxygen species (ROS) accumulation and cell apoptosis. TrxR-IN-6 induces mitochondrial dysfunction, endoplasmic reticulum stress and DNA damage. TrxR-IN-6 can be used for the research of breast cancer, leukemia.
    TrxR-IN-6
  • HY-146350
    TrxR-IN-4
    		Inhibitor
    TrxR-IN-4 is a thioredoxin reductase (TrxR) inhibitor with a rat IC50 of 0.37 μM. TrxR-IN-4 inhibits TrxR activity, elevates reactive oxygen species (ROS) and induces apoptosis. TrxR-IN-4 mediates endoplasmic reticulum stress and induces mitochondrial dysfunction. TrxR-IN-4 can be used for the research of hepatocellular carcinoma.
    TrxR-IN-4
  • HY-183544
    Platinum(IV) Prodrug-1
    		Inhibitor
    Platinum (IV) Prodrug-1 is a Pt (IV) prodrug and selective TrxR1 inhibitor. Platinum (IV) Prodrug-1 induces ferroptosis (Ferroptosis) by depleting glutathione, accumulating intracellular lipid peroxides, and inactivating Glutathione peroxidase 4. Platinum (IV) Prodrug-1 triggers endoplasmic reticulum stress and immunogenic cell death via excessive accumulation of intracellular ROS. Platinum (IV) Prodrug-1 exhibits anticancer activity against both Cisplatin (HY-17394)-sensitive and Cisplatin-resistant triple-negative breast cancer cells. Platinum (IV) Prodrug-1 can be used for the research of triple-negative breast cancer.
    Platinum(IV) Prodrug-1
  • HY-172086
    TrxR-IN-7
    		Inhibitor
    TrxR-IN-7 is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 3.5 μM. TrxR-IN-7 induces reactive oxygen species (ROS) generation and apoptosis in tumor cells. TrxR-IN-7 can be used for the research of liver cancer and breast cancer.
    TrxR-IN-7
  • HY-168874
    TrxR1-IN-2
    		Inhibitor
    TrxR1-IN-2 (Compound 6a) is a TrxR1 inhibitor that covalently binds to the Cys475 and Sec498 sites of TrxR1, thereby inhibiting TrxR1 activity and leading to redox homeostasis disruption, which triggers apoptosis and ferroptosis.
    TrxR1-IN-2
  • HY-163724
    LW-216
    		Inhibitor
    LW-216 is a TrxR1 inhibitor that induces Apoptosis. LW-216 has anti-tumor activity.
    LW-216
  • HY-151802
    CPUL1
    CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective.
    CPUL1
  • HY-168492
    TrxR/EGFR-IN-1
    		Inhibitor
    TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor. TrxR/EGFR-IN-1 is active against both Gefitinib (HY-50895)-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. TrxR/EGFR-IN-1 promotes the degradation of GPX4 protein through autophagolysosomal and proteasomal pathways, leading to ferroptosis. In addition, TrxR/EGFR-IN-1 can induce endoplasmic reticulum stress and trigger immunogenic cell death. TrxR/EGFR-IN-1 can be used for the research of Gefitinib (HY-50895)-resistant lung cancer.
    TrxR/EGFR-IN-1
  • HY-182324
    TrxR2-IN-1
    		Inhibitor
    TrxR2-IN-1 is a thioredoxin reductase 2 (TrxR2) inhibitor with an IC50 value of 0.83 μM. TrxR2-IN-1 accumulates in mitochondria, impairs mitochondrial function and membrane potential, increases reactive oxygen species (ROS) levels, activates ASK1-mediated caspase-dependent apoptosis (apoptosis), induces G2/M cell cycle arrest, and inhibits cancer cell migration. TrxR2-IN-1 can be used in the research of hepatocellular carcinoma.
    TrxR2-IN-1
  • HY-173403
    TrxR-IN-8
    		Inhibitor
    TrxR-IN-8 (Compound 6f) is a selective TrxR inhibitor (IC50: 10.2 μM). TrxR-IN-8 induces apoptosis through oxidative stress by stimulating the production of reactive oxygen species (ROS), reducing intracellular thiols, and lowering the glutathione/glutathione ratio. TrxR-IN-8 exhibits significant cytotoxicity against non-small cell lung cancer (NSCLC) cells.
    TrxR-IN-8
  • HY-162958
    Photosensitizer-6
    		Inhibitor
    Photosensitizer-6 (Compound 4) is a gold (I) complex and exhibits inhibitory activity against TrxR. Photosensitizer-6 induces apoptosis in 4T1 cell, targets and eradicates tumors through chemo-phototherapy and immunogenic cell death under light exposure. Photosensitizer-6 can be used for tumor imaging.
    Photosensitizer-6
  • HY-W504391
    Nitrovin
    		Inhibitor
    Nitrovin is an antibacterial growth promoter. Nitrovin induces ROS-mediated non-apoptotic and apoptotic-like cell death by targeting TrxR1. Nitrovin has anticancer activity, with IC50 values of 1.31-6.60 μM for tumor and normal cells.
    Nitrovin
  • HY-159883
    DDHF20
    		Inhibitor
    DDHF20 is an antimicrobial agent against Staphylococcus aureus, targeting and inhibiting its thioredoxin reductase (TrxR). It acts as a competitive inhibitor for the NADPH binding site. DDHF20 is expected to be used in research related to antimicrobial infections caused by Staphylococcus aureus.
    DDHF20
  • HY-120914
    TrxR1-IN-B19
    		Inhibitor
    TrxR1-IN-B19 (GO-Y015) (Compound B19) is a Curcumin (HY-N0005) derivative and colvalent TrxR1 inhibitor. TrxR1-IN-B19 inhibits TrxR1 enzyme activity to elevate oxidative stress, and then induce ROS-mediated ER Stress and mitochondrial dysfunction, subsequently resulting in cell cycle arrest and apoptosis.
    TrxR1-IN-B19
  • HY-182683
    MMV085203
    		Inhibitor
    MMV085203 is a potent Plasmodium falciparum inhibitor, with a PfTrxR EC50 of 900 nM. MMV085203 exerts potent antimalarial activity against both blood‑stage and sexual‑stage Plasmodium falciparum parasites, with superior efficacy toward clinical isolates of high clonal diversity. MMV085203 modulates parasite redox homeostasis, induces ROS production, and elevates mitochondrial TCA cycle intermediates. MMV085203 can be used for the research of malaria.
    MMV085203
  • HY-113958R
    Difethialone (Standard)
    		Antagonist
    Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts.
    Difethialone (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
TrxR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.